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Gastrointestinal stromal tumors (GISTs) are the most common
mesenchymal tumors of the gastrointestinal tract. For many years,
GISTs were regarded as smooth muscle tumors and often misclassiﬁed
as leiomyomas or leiomyosarcomas. With regard to the latter
diagnosis, the treatment of advanced ‘‘leiomyosarcomas’’ was
associated with dismal results utilizing various chemotherapy regi-
mens. Subsequent electron microscopy and immunohistochemical
staining reveal that GISTs do not have features of smooth muscle
tumors. It is now known that the vast majority of GISTs express the
oncogene, KIT, which is not the case for leiomyomas or leiomyo-
sarcomas. It turned out that mutations in KIT were instrumental in the
pathogenesis of GISTs. Ever since 2001, the treatment of GISTs has
undergone a revolution because of a case report of a patient with
advanced GIST who had a dramatic clinical response to a tyrosine
kinase inhibitor [1]. Though other molecularly targeted therapies were
being used in oncology, imatinib was one of the ﬁrst that was
speciﬁcally designed to inhibit the product of a constitutively
activating mutation that drives pathogenesis of a solid tumor. Its use
served as a ‘‘paradigm’’ of molecularly targeted therapies for
malignancies. The wild success of molecularly targeted therapy has
led vastly improved outcomes. Certainly, there have been ongoing
changes in the management of GISTs, particularly in advanced or
metastatic cases.
In this issue of Seminars in Surgical Oncology, we have put together a
multidisciplinary group of experts to cover some of the most relevant
topics in the management of GISTs. We have solicited a historical
perspective on GISTs and contrasted it with the current use of
histopathology and molecular diagnostics. Surgical approaches
(including indications and timing of operations) have necessarily
changed with vastly improved systemic treatments. With evolving
treatments, it is necessary to consider new approaches to imaging
modalities for diagnosis and surveillance. Finally, a chapter is devoted
to special consideration with pediatric GISTs. Our increasing knowl-
edge regarding the molecular events leading to cancer pathogenesis
and metastasis will modify our treatment approaches including
surgical therapies in the future.
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